Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-103731
Filing Date
2023-04-17
Accepted
2023-04-17 16:47:57
Documents
4
Period of Report
2023-06-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A d449732ddef14a.htm DEF 14A 717728
2 GRAPHIC g449732g11w06.jpg GRAPHIC 95228
3 GRAPHIC g449732g82k44.jpg GRAPHIC 4336
4 GRAPHIC g449732g90m21.jpg GRAPHIC 92650
  Complete submission text file 0001193125-23-103731.txt   983960
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 23824483
SIC: 2834 Pharmaceutical Preparations